When was Senseera founded?

Senseera was founded in 2020 and raised its 1st funding round 5 years after it was founded.

Where is Senseera located?

Senseera is headquartered in Jerusalem, Israel.

How many employees does Senseera have?

As of Jul 31, 2026, the latest employee count at Senseera is 19.

Is Senseera a funded company?

Senseera is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 07, 2025.

When was the latest funding round of Senseera?

Senseera's latest funding was a $***** Seed round on Jan 07, 2025, with participation from 3 investors.

Where does Senseera rank among its competitors?

Senseera ranks 34th amongst 155 active competitors, of which 56 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Senseera?

Senseera's top competitors include Guardant Health, GRAIL and BillionToOne. Among them, GRAIL secured the most recent funding round in June, 2026.

Senseera - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of liquid biopsy blood tests for cancer diagnosis. The cfChIP-seq technology can detect cell-free chromatin tissue which can be used to identify patient-specific gene expression for the detection of diseases and treatment response. The company uses molecular biology, next-generation sequencing, and computational analysis to extract epigenetic information.

Website: senseerahealth.com
Email ID: *****@senseerahealth.com

Key Metrics

Founded Year

2020

Location

Jerusalem, Israel

Stage

Seed

Total Funding

$7.1M in 1 round

Latest Funding Round

Seed, Jan 07, 2025, $*****

Investors

Lightspeed Venture Partners & 2 more

Ranked

34^th among 155 active competitors

Employee Count

19 as on Jul 31, 2026

Similar Companies

Guardant Health & 156 more

View Senseera's full profile

Senseera has raised a total funding of $7.1M over 1 round. Its latest funding round was a Seed round on Jan 07, 2025 for $*****. 3 investors participated in its latest round. Senseera has 3 institutional investors.

Here is the list of recent funding rounds of Senseera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2025	9145313	Seed	9022965	9728556	3660968	1552011

Access funding benchmarks and valuations. Sign up today!

View details of Senseera's funding rounds and investors

The founders of Senseera is Ronen Sadeh.

Here are the details of Senseera's key team members:

Ronen Sadeh: Co-Founder of Senseera.

View details of Senseera's Founder profiles and Board Members

Senseera's employee count trend

Senseera has 19 employees as of Jul 26. Here is Senseera's employee count trend over the years:

Uncover Senseera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Senseera include Guardant Health, GRAIL and BillionToOne. Here is the list of Top 10 competitors of Senseera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Orbimed, SoftBank Vision Fund & 25 others	75/100
2nd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Google Ventures & 52 others	71/100
3rd	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
4th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
5th	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	Perceptive Advisors, RA Capital Management ... & 65 others	66/100
6th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	65/100
7th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
8th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 19 others	63/100
9th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
10th	Naveris 2017, Waltham (United States), Acquired	Provider of blood tests for early cancer detection	$68.5M	Gurnet Point Capital, B-FLEXION & 3 others	60/100
34th	Senseera 2020, Jerusalem (Israel), Seed	Provider of liquid biopsy blood tests for cancer diagnosis	$7.1M	Lightspeed Venture Partners, Lmri & 1 others	43/100